<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>vMTB Consultation Report | None</title>
  <style>
    :root {
      --primary: #0d47a1;
      --secondary: #546e7a;
      --accent: #00838f;
      --warning: #f57c00;
      --danger: #c62828;
      --success: #2e7d32;
      --bg: #ffffff;
      --bg-alt: #f5f7fa;
      --text: #212121;
      --text-light: #616161;
      --border: #e0e0e0;
    }

    * { box-sizing: border-box; margin: 0; padding: 0; }

    body {
      font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", "Microsoft YaHei", sans-serif;
      background: var(--bg-alt);
      color: var(--text);
      line-height: 1.6;
      font-size: 14px;
      padding: 20px;
    }

    .container {
      max-width: 1100px;
      margin: 0 auto;
      background: var(--bg);
      box-shadow: 0 1px 3px rgba(0,0,0,0.1);
    }

    header {
      background: var(--primary);
      color: white;
      padding: 24px 32px;
      display: flex;
      justify-content: space-between;
      align-items: center;
    }

    header h1 {
      font-size: 20px;
      font-weight: 600;
      letter-spacing: 0.5px;
    }

    .header-meta {
      text-align: right;
      font-size: 12px;
      opacity: 0.9;
    }

    .section {
      padding: 24px 32px;
      border-bottom: 1px solid var(--border);
    }

    .section-title {
      font-size: 16px;
      font-weight: 600;
      color: var(--primary);
      margin-bottom: 16px;
      padding-bottom: 8px;
      border-bottom: 2px solid var(--primary);
    }

    h2 {
      color: var(--primary);
      font-size: 1.3em;
      margin-top: 24px;
      margin-bottom: 12px;
      padding-bottom: 8px;
      border-bottom: 2px solid var(--primary);
    }

    h3 {
      color: var(--secondary);
      font-size: 1.1em;
      margin-top: 16px;
      margin-bottom: 8px;
    }

    p { margin-bottom: 12px; }

    ul, ol {
      margin-left: 20px;
      margin-bottom: 12px;
    }

    li { margin-bottom: 6px; }

    /* Info Grid */
    .info-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
      gap: 16px;
    }

    .info-item {
      padding: 12px;
      background: var(--bg-alt);
      border-radius: 4px;
    }

    .info-item label {
      font-size: 11px;
      color: var(--text-light);
      text-transform: uppercase;
      letter-spacing: 0.5px;
      display: block;
      margin-bottom: 4px;
    }

    .info-item span { font-size: 14px; font-weight: 500; }

    /* Tables */
    table {
      width: 100%;
      border-collapse: collapse;
      font-size: 13px;
      margin: 16px 0;
    }

    th, td {
      padding: 10px 12px;
      text-align: left;
      border: 1px solid var(--border);
    }

    th {
      background: var(--bg-alt);
      font-weight: 600;
      color: var(--secondary);
    }

    tr:nth-child(even) { background: var(--bg-alt); }

    /* Badges */
    .badge {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 3px;
      font-size: 11px;
      font-weight: 600;
    }

    .badge-success { background: #e8f5e9; color: var(--success); }
    .badge-warning { background: #fff3e0; color: var(--warning); }
    .badge-danger  { background: #ffebee; color: var(--danger); }
    .badge-info    { background: #e3f2fd; color: var(--primary); }
    .badge-secondary { background: #eceff1; color: var(--secondary); }
    .badge-primary { background: var(--primary); color: white; }

    /* Executive Summary */
    .exec-summary {
      background: var(--bg-alt);
      padding: 20px;
      border-radius: 4px;
      border-left: 4px solid var(--primary);
      margin-bottom: 20px;
    }

    .exec-summary h3 {
      font-size: 14px;
      color: var(--primary);
      margin-bottom: 12px;
    }

    .exec-summary ul { list-style: none; padding: 0; margin: 0; }

    .exec-summary li {
      padding: 6px 0;
      border-bottom: 1px solid var(--border);
    }

    .exec-summary li:last-child { border-bottom: none; }

    /* Card Grid */
    .card-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
      gap: 16px;
      margin: 16px 0;
    }

    .card {
      border: 1px solid var(--border);
      border-radius: 4px;
      padding: 16px;
    }

    .card-header {
      font-weight: 600;
      color: var(--primary);
      margin-bottom: 12px;
      padding-bottom: 8px;
      border-bottom: 1px solid var(--border);
    }

    /* Treatment Timeline */
    .treatment-timeline {
      position: relative;
      padding-left: 60px;
      margin: 20px 0;
    }

    .treatment-timeline::before {
      content: '';
      position: absolute;
      left: 24px;
      top: 0;
      bottom: 0;
      width: 2px;
      background: var(--border);
    }

    .treatment-item {
      position: relative;
      margin-bottom: 16px;
      display: flex;
      align-items: flex-start;
    }

    .treatment-marker {
      position: absolute;
      left: -60px;
      width: 48px;
      height: 48px;
      background: var(--primary);
      color: white;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 600;
      font-size: 14px;
      z-index: 1;
    }

    .treatment-marker.event { background: var(--secondary); }
    .treatment-marker.adjuvant { background: #7e57c2; }
    .treatment-marker.maint { background: #26a69a; }
    .treatment-marker.pd { background: var(--danger); }
    .treatment-marker.current { background: var(--warning); color: var(--text); }
    .treatment-marker.surgery { background: var(--secondary); }
    .treatment-marker.neoadjuvant { background: var(--primary); }

    .treatment-content {
      flex: 1;
      background: var(--bg-alt);
      border-radius: 4px;
      padding: 12px 16px;
      border-left: 3px solid var(--primary);
    }

    .treatment-item.event .treatment-content { border-left-color: var(--secondary); }
    .treatment-item.adjuvant .treatment-content { border-left-color: #7e57c2; }
    .treatment-item.maint .treatment-content { border-left-color: #26a69a; }
    .treatment-item.pd .treatment-content { border-left-color: var(--danger); }
    .treatment-item.surgery .treatment-content { border-left-color: var(--secondary); }

    .treatment-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      margin-bottom: 8px;
    }

    .treatment-date { font-weight: 600; color: var(--primary); }
    .treatment-body { font-size: 14px; }

    .treatment-note {
      font-size: 12px;
      margin-top: 6px;
      padding-left: 8px;
      border-left: 2px solid var(--border);
      color: var(--text-light);
    }

    /* Key Recommendations */
    .key-rec {
      display: flex;
      align-items: flex-start;
      padding: 12px;
      background: var(--bg-alt);
      margin-bottom: 8px;
      border-radius: 4px;
    }

    .key-rec-num {
      width: 24px;
      height: 24px;
      background: var(--primary);
      color: white;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 12px;
      font-weight: 600;
      margin-right: 12px;
      flex-shrink: 0;
    }

    /* Inline Citations with Tooltip */
    .cite {
      color: var(--primary);
      cursor: pointer;
      text-decoration: none;
      font-size: 11px;
      vertical-align: super;
      font-weight: 600;
    }
    .cite:hover { text-decoration: underline; }

    .ref-tooltip {
      position: relative;
      display: inline;
    }

    .ref-tooltip .ref-text {
      visibility: hidden;
      background: #333;
      color: #fff;
      padding: 10px 14px;
      border-radius: 6px;
      position: absolute;
      z-index: 100;
      bottom: 125%;
      left: 50%;
      transform: translateX(-50%);
      width: 350px;
      font-size: 12px;
      line-height: 1.5;
      white-space: normal;
      box-shadow: 0 4px 12px rgba(0,0,0,0.3);
    }

    .ref-tooltip .ref-text::after {
      content: '';
      position: absolute;
      top: 100%;
      left: 50%;
      margin-left: -6px;
      border-width: 6px;
      border-style: solid;
      border-color: #333 transparent transparent transparent;
    }

    .ref-tooltip:hover .ref-text { visibility: visible; }

    /* Evidence Tags */
    .evidence {
      font-size: 10px;
      padding: 1px 6px;
      border-radius: 2px;
      margin-left: 6px;
    }

    .evidence-high   { background: #c8e6c9; color: var(--success); }
    .evidence-medium { background: #fff9c4; color: #f57f17; }
    .evidence-low    { background: #ffcdd2; color: var(--danger); }

    .evidence-tag {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 4px;
      font-size: 11px;
      font-weight: 500;
      margin-left: 5px;
    }

    .evidence-a { background: #dcfce7; color: #166534; }
    .evidence-b { background: #dbeafe; color: #1e40af; }
    .evidence-c { background: #fef3c7; color: #92400e; }
    .evidence-d { background: #fee2e2; color: #991b1b; }

    /* Calculation Box */
    .calc-box {
      background: var(--bg-alt);
      padding: 16px;
      border-radius: 4px;
      font-family: "SF Mono", Monaco, monospace;
      font-size: 13px;
      margin: 12px 0;
    }

    .calc-box h4 {
      font-family: -apple-system, sans-serif;
      font-size: 13px;
      margin-bottom: 8px;
    }

    /* Drug Comparison Row */
    .drug-row {
      display: grid;
      grid-template-columns: 140px repeat(4, 1fr);
      gap: 1px;
      background: var(--border);
      margin-bottom: 16px;
    }

    .drug-row > div {
      background: var(--bg);
      padding: 10px;
      font-size: 13px;
    }

    .drug-row .drug-name {
      background: var(--primary);
      color: white;
      font-weight: 600;
    }

    /* Warning Box */
    .warning-box {
      background: #fef2f2;
      border-left: 4px solid var(--danger);
      padding: 15px 20px;
      margin: 20px 0;
      border-radius: 0 8px 8px 0;
    }

    .warning-box strong {
      color: var(--danger);
    }

    /* Info Box */
    .info-box {
      background: var(--bg-alt);
      border-left: 4px solid var(--primary);
      padding: 15px 20px;
      margin: 20px 0;
      border-radius: 0 8px 8px 0;
    }

    /* Utility Classes */
    .highlight { background: #fff9c4; padding: 0 2px; }
    .text-danger { color: var(--danger); }
    .text-success { color: var(--success); }
    .text-warning { color: var(--warning); }

    /* Reference Links */
    .reference {
      color: var(--primary);
      text-decoration: none;
      transition: color 0.2s;
    }

    .reference:hover {
      color: var(--accent);
      text-decoration: underline;
    }

    /* Footer */
    footer {
      padding: 16px 32px;
      background: var(--bg-alt);
      text-align: center;
      font-size: 11px;
      color: var(--text-light);
    }

    /* Print Styles */
    @media print {
      body { background: white; padding: 0; }
      .container { box-shadow: none; }
      .section { page-break-inside: avoid; }
      .ref-tooltip .ref-text { display: none; }
    }

    /* Content Area */
    .content {
      padding: 24px 32px;
    }
  </style>
</head>
<body>
  <div class="container">

    <!-- Header -->
    <header>
      <h1>虚拟分子肿瘤委员会会诊报告</h1>
      <div class="header-meta">
        <div>vMTB Consultation Report</div>
        <div>患者编号: None</div>
        <div>肿瘤类型: 乙状结肠癌</div>
        <div>报告日期: 2026-01-17 14:52:15</div>
      </div>
    </header>

    <!-- Report Content -->
    <div class="content">
      <p>这里是基于多学科专家（遗传学、临床试验、肿瘤内科）意见汇总生成的最终 MTB 报告。</p>
<hr />
<h2>1. 执行摘要 (Executive Summary)</h2>
<div class="exec-summary"><h3>执行摘要</h3><ul><li><strong>患者:</strong> 70岁男性，乙状结肠癌 IV期</li><li><strong>关键分子特征:</strong> KRAS G12C (11.5%), TMB-High (79.0 mut/Mb), ATM Germline, 肾功能不全 (Cr 146 μmol/L)</li><li><strong>当前状态:</strong> 既往接受 10 线治疗，疾病进展</li><li><strong>核心建议:</strong> 索托拉西布 (Sotorasib) + 帕尼单抗 (Panitumumab)</li><li><strong>紧急程度:</strong> 常规</li></ul></div>

<p><strong>摘要</strong>:<br />
患者为极多线治疗后的难治性结直肠癌，存在明确的 <strong>KRAS G12C</strong> 驱动突变和极高的 <strong>TMB (79 mut/Mb)</strong>。鉴于患者存在肾功能不全（肌酐 146 μmol/L），且既往治疗已耗尽标准方案，首选推荐 <strong>KRAS G12C 抑制剂联合抗 EGFR 单抗</strong>（CodeBreaK 300 模式），该方案不经肾脏排泄，安全性与疗效最佳。备选方案为免疫检查点抑制剂（PD-1），基于 TMB-High 特征。</p>
<hr />
<h2>2. 患者概况 (Patient Profile)</h2>
<h3>人口学特征</h3>
<ul>
<li><strong>年龄</strong>: 70岁</li>
<li><strong>性别</strong>: 男</li>
<li><strong>ECOG PS</strong>: 1 (体能尚可)</li>
</ul>
<h3>肿瘤诊断</h3>
<ul>
<li><strong>原发灶</strong>: 乙状结肠癌</li>
<li><strong>病理</strong>: 腺癌</li>
<li><strong>分期</strong>: IV期 (晚期难治性)</li>
<li><strong>治疗史</strong>: 既往已接受 10 线系统治疗</li>
</ul>
<h3>合并症与器官功能</h3>
<ul>
<li><strong>肾功能</strong>: <strong>异常</strong> ⚠️ (血肌酐 146 μmol/L, eGFR 估算约 35-45 mL/min)</li>
<li><strong>其他</strong>: 无具体描述，假设肝功能及骨髓功能尚可。</li>
</ul>
<hr />
<h2>3. 分子特征 (Molecular Profile)</h2>
<h3>可行动变异 (Actionable Alterations)</h3>
<table>
<thead>
<tr>
<th>基因</th>
<th>变异</th>
<th>类型</th>
<th>VAF</th>
<th>CIViC Level</th>
<th>证据来源</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KRAS</strong></td>
<td><strong>G12C</strong></td>
<td>SNV</td>
<td>11.5%</td>
<td>Level A</td>
<td>FDA Approved (CRC Combo)</td>
</tr>
<tr>
<td><strong>TMB</strong></td>
<td><strong>79.0 mut/Mb</strong></td>
<td>Biomarker</td>
<td>High</td>
<td>Level A</td>
<td>FDA Approved (Solid Tumors)</td>
</tr>
<tr>
<td><strong>ATM</strong></td>
<td>Germline</td>
<td>SNV</td>
<td>-</td>
<td>Level C</td>
<td>Basket Trials (PARPi)</td>
</tr>
</tbody>
</table>
<h3>免疫生物标志物</h3>
<ul>
<li><strong>MSI 状态</strong>: MSS (微卫星稳定)</li>
<li><strong>TMB</strong>: <strong>79.0 mut/Mb (High)</strong> —— 强烈提示 POLE/POLD1 突变 ("Ultramutated" 表型)</li>
<li><strong>PD-L1</strong>: 0%</li>
</ul>
<h3>变异解读</h3>
<ol>
<li><strong>KRAS G12C</strong>: 结直肠癌中单药 G12C 抑制剂效果差，必须联合抗 EGFR 抗体以阻断反馈通路。</li>
<li><strong>TMB-High (MSS)</strong>: 尽管是 MSS，但极高的 TMB 使得该肿瘤具有高免疫原性，PD-1 抗体治疗可能带来长生存。</li>
<li><strong>ATM</strong>: 提示遗传易感性，且可能对 PARP 抑制剂或铂类药物敏感（但在 10 线治疗后，铂类可能已耐药或受限于肾功能）。</li>
</ol>
<hr />
<h2>4. 治疗史回顾 (Treatment History)</h2>
<div class="treatment-timeline">
            <div class="treatment-item adjuvant">
              <div class="treatment-marker adjuvant">1-9线</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">既往史</span>
                  <span class="badge badge-info">最终PD</span>
                </div>
                <div class="treatment-body"><strong>氟尿嘧啶/奥沙利铂/伊立替康/贝伐珠单抗/瑞戈非尼等</strong></div>
                <div class="treatment-note">标准治疗已耗尽</div>
              </div>
            </div>
            <div class="treatment-item pd">
              <div class="treatment-marker pd">10线</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">近期</span>
                  <span class="badge badge-danger">PD</span>
                </div>
                <div class="treatment-body"><strong>未知方案</strong></div>
                <div class="treatment-note">疾病进展</div>
              </div>
            </div>
            <div class="treatment-item current">
              <div class="treatment-marker current">当前</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">拟定</span>
                  <span class="badge badge-info">计划中</span>
                </div>
                <div class="treatment-body"><strong>索托拉西布+帕尼单抗</strong></div>
                <div class="treatment-note">靶向联合治疗</div>
              </div>
            </div></div>

<p><strong>关键观察</strong>:<br />
- 患者已耐受 10 线治疗，说明肿瘤生长相对惰性或患者体质较好。<br />
- 肾功能受损可能是既往多线化疗（如铂类）累积毒性所致。</p>
<hr />
<h2>5. 药物/方案对比 (Regimen Comparison)</h2>
<p>针对末线 KRAS G12C / TMB-H 患者的方案权衡：</p>
<table>
<thead>
<tr>
<th>方案</th>
<th>证据等级</th>
<th>ORR</th>
<th>mPFS</th>
<th>关键毒性</th>
<th>肾功能安全性</th>
<th>中国可及性</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sotorasib + Panitumumab</strong></td>
<td><strong>A (Phase III)</strong></td>
<td>~30%</td>
<td>5.6m</td>
<td>皮疹, 低镁</td>
<td><strong>安全</strong> (肝代谢/大分子)</td>
<td>均已上市(超适应症)</td>
</tr>
<tr>
<td><strong>Pembrolizumab (PD-1)</strong></td>
<td><strong>B (TMB-H)</strong></td>
<td>~40%*</td>
<td>未知</td>
<td>免疫性炎症</td>
<td><strong>安全</strong></td>
<td>已上市(超适应症)</td>
</tr>
<tr>
<td><strong>Glecirasib + JAB-3312</strong></td>
<td>C (Phase I/II)</td>
<td>探索性</td>
<td>探索性</td>
<td>胃肠道反应</td>
<td>⚠️ 需筛选 (通常要求Cr正常)</td>
<td>临床试验 (招募中)</td>
</tr>
<tr>
<td><strong>TAS-102 / Regorafenib</strong></td>
<td>A (SOC)</td>
<td>&lt;5%</td>
<td>2.0m</td>
<td>骨髓抑制, 手足综</td>
<td>⚠️ TAS-102需减量</td>
<td>医保报销</td>
</tr>
</tbody>
</table>
<p><strong>对比总结</strong>: <br />
<strong>Sotorasib + Panitumumab</strong> 拥有最强的循证医学证据（CodeBreaK 300）且对肾功能影响最小，为首选。PD-1 单抗是极具吸引力的备选（高 TMB），且同样肾脏安全。</p>
<hr />
<h2>6. 器官功能与剂量 (Organ Function &amp; Dosing)</h2>
<h3>限制性器官：肾脏 (Renal System)</h3>
<ul>
<li><strong>现状</strong>: 血肌酐 146 μmol/L (eGFR &lt; 50 mL/min)。</li>
<li><strong>风险</strong>: 药物排泄减慢，毒性蓄积。</li>
</ul>
<h3>剂量调整建议</h3>
<p><strong>推荐方案: Sotorasib + Panitumumab</strong><br />
- <strong>Sotorasib (索托拉西布)</strong>:<br />
  - <strong>剂量</strong>: 960 mg PO QD (标准剂量)。<br />
  - <strong>调整</strong>: 轻中度肾受损无需调整。主要经肝脏代谢及粪便排泄。<br />
- <strong>Panitumumab (帕尼单抗)</strong>:<br />
  - <strong>剂量</strong>: 6 mg/kg IV Q2W。<br />
  - <strong>调整</strong>: 无需调整（单克隆抗体不经肾脏消除）。</p>
<p><strong>药物相互作用 (DDI) 警示 ⚠️</strong>:<br />
- <strong>质子泵抑制剂 (PPIs)</strong>: Sotorasib 依赖胃酸吸收。<strong>禁止</strong>与奥美拉唑等 PPI 同服。若必须抑酸，改用法莫替丁（H2RA）并错开 12 小时服用。</p>
<hr />
<h2>7. 治疗路线图 (Treatment Roadmap)</h2>
<div class="card-grid">
            <div class="card" style="border-left: 4px solid var(--warning);">
              <div class="card-header">当前推荐 (11线)</div>
              <p><strong>索托拉西布 (960mg QD) + 帕尼单抗 (6mg/kg Q2W)</strong></p>
              <ul><li>停用 PPI 类药物</li><li>每 2 周监测电解质 (Mg++)</li><li>预防性使用多西环素 (皮疹)</li></ul>
            </div>
            <div class="card" style="border-left: 4px solid var(--secondary);">
              <div class="card-header">备选方案 (若经济受限)</div>
              <p><strong>PD-1 单抗 (如替雷利珠单抗)</strong></p>
              <ul><li>基于 TMB 79 mut/Mb</li><li>确认无自身免疫病史</li><li>肾功能安全</li></ul>
            </div>
            <div class="card" style="border-left: 4px solid var(--secondary);">
              <div class="card-header">临床试验</div>
              <p><strong>NCT05288205 (Glecirasib)</strong></p>
              <ul><li>需核实肌酐入组标准</li><li>优先联系北京协和/安徽省立</li></ul>
            </div></div>

<h3>理由陈述</h3>
<ul>
<li><strong>首选联合靶向</strong>: 基于 CodeBreaK 300 数据，该方案在三线及后线治疗中显著优于标准治疗<span class="ref-tooltip">
              <a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37870968" target="_blank">[P1]</a>
              <span class="ref-text">CodeBreaK 300: mPFS 5.6m vs 2.2m</span>
            </span> <span class="evidence-tag evidence-a">Evidence A</span>。且该方案避开了肾毒性。</li>
<li><strong>次选免疫</strong>: TMB 79 极高，提示潜在 POLE 突变，PD-1 可能带来"治愈性"效果，但作为 11 线治疗，靶向联合方案的数据更稳健。</li>
</ul>
<hr />
<h2>8. 分子复查建议 (Re-biopsy / Liquid Biopsy)</h2>
<p><strong>时机</strong>: 治疗 2-3 个周期后或疾病进展时。<br />
<strong>方式</strong>: 液体活检 (ctDNA)。<br />
<strong>目的</strong>:<br />
1.  监测 KRAS G12C 丰度变化（疗效反应）。<br />
2.  检测获得性耐药突变：如 <strong>MET 扩增</strong>、<strong>EGFR 胞外域突变</strong> 或 <strong>KRAS 新发突变</strong>。</p>
<hr />
<h2>9. 临床试验推荐 (Clinical Trials)</h2>
<p>鉴于患者肾功能不全（Cr 146），入组临床试验难度较大（通常要求 Cr ≤ 1.5x ULN 或 CrCl ≥ 60）。建议优先考虑上市药物超适应症使用。若肾功能改善，可尝试：</p>
<h3>推荐试验 (中国中心)</h3>
<h4>Trial 1: <a href="https://clinicaltrials.gov/study/NCT05288205" class="reference" target="_blank">[NCT05288205]</a> - Glecirasib + JAB-3312</h4>
<p><strong>阶段</strong>: Phase I/IIa<br />
<strong>药物</strong>: KRAS G12C 抑制剂 + SHP2 抑制剂<br />
<strong>状态</strong>: 招募中<br />
<strong>中心</strong>: 北京协和医院、中国科大附一院（合肥）<br />
<strong>资格</strong>: 需确认 CrCl 是否满足要求。<br />
<strong>理由</strong>: 双靶点阻断克服耐药，国产原研药物。</p>
<hr />
<h2>10. 局部治疗建议 (Local Therapy)</h2>
<p><strong>当前状态</strong>: 广泛期转移，且为 10 线治疗后。<br />
<strong>建议</strong>:<br />
- <strong>暂不推荐</strong> 根治性局部治疗。<br />
- <strong>姑息放疗</strong>: 仅在出现骨转移疼痛或肿瘤压迫症状时考虑。注意放疗区域尽量避开肾脏，以免加重肾功能损伤。</p>
<hr />
<h2>11. 核心建议汇总 (Core Recommendations)</h2>
<h3>推荐治疗方案</h3>
<ol>
<li>
<p><strong>首选方案</strong>: <strong>索托拉西布 (Sotorasib) + 帕尼单抗 (Panitumumab)</strong></p>
<ul>
<li><strong>证据等级</strong>: <strong><span class="evidence-tag evidence-a">Evidence A</span></strong> (CodeBreaK 300 Phase III)</li>
<li><strong>剂量</strong>: Sotorasib 960mg PO QD + Panitumumab 6mg/kg IV Q2W。</li>
<li><strong>注意</strong>: 严格停用 PPI 类胃药；预防性处理皮疹。</li>
</ul>
</li>
<li>
<p><strong>强力备选</strong>: <strong>PD-1 抑制剂 (如帕博利珠单抗/替雷利珠单抗)</strong></p>
<ul>
<li><strong>证据等级</strong>: <strong><span class="evidence-tag evidence-b">Evidence B</span></strong> (TMB-H &gt; 10 mut/Mb)</li>
<li><strong>理由</strong>: TMB 79.0 mut/Mb 提示极高免疫原性。若经济受限或靶向不耐受，可直接尝试。</li>
</ul>
</li>
</ol>
<h3>不推荐 (Not Recommended) ❌</h3>
<ol>
<li><strong>单药抗 EGFR 抗体</strong>: KRAS G12C 突变导致下游通路激活，单药无效 <strong><span class="evidence-tag evidence-a">Evidence A</span></strong>。</li>
<li><strong>全剂量化疗 (尤其是卡培他滨/顺铂)</strong>: 因肾功能不全 (Cr 146)，极易导致严重毒性。</li>
<li><strong>质子泵抑制剂 (PPI)</strong>: 与 Sotorasib 合用会大幅降低药物暴露量，导致治疗失败。</li>
</ol>
<h3>监测与随访</h3>
<ul>
<li><strong>每 2 周</strong>: 查血常规、生化（关注肌酐、镁离子、肝酶）。</li>
<li><strong>每 8 周</strong>: CT 评估疗效。</li>
</ul>
<hr />
<h2>12. 参考文献 (References)</h2>
<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/37870968/">PMID: 37870968 - CodeBreaK 300: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/36542100/">PMID: 36542100 - KRYSTAL-1: Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/33020664/">PMID: 33020664 - KEYNOTE-158: Pembrolizumab in TMB-High Solid Tumors</a></li>
<li><a href="https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1428">NCCN Guidelines for Colon Cancer v1.2025</a></li>
<li><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf">FDA Label - Sotorasib (Lumakras)</a></li>
</ol>

      
      <div class="warning-box">
        <strong>⚠️ 安全警告</strong>
        <ul>
        
          <li>- **肾功能**: **异常** ⚠️ (血肌酐 146 μmol/L, eGFR 估算约 35-45 mL/min)</li>
        
          <li>| **Glecirasib + JAB-3312** | C (Phase I/II) | 探索性 | 探索性 | 胃肠道反应 | ⚠️ 需筛选 (通常要求Cr正常) | 临床试验 (招募中) |</li>
        
          <li>| **TAS-102 / Regorafenib** | A (SOC) | &lt;5% | 2.0m | 骨髓抑制, 手足综 | ⚠️ TAS-102需减量 | 医保报销 |</li>
        
          <li>**药物相互作用 (DDI) 警示 ⚠️**:</li>
        
          <li>不推荐 (Not Recommended) ❌</li>
        
        </ul>
      </div>
      

      
    </div>

    <footer>
      <p><strong>免责声明:</strong> 本报告仅供临床参考。具体治疗决策应由主治医师根据患者实际情况和最新临床证据综合判断。</p>
      <p>虚拟分子肿瘤委员会会诊报告 | 生成日期: 2026-01-17 14:52:15</p>
    </footer>

  </div>
</body>
</html>